Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Stage IV Breast Cancer
Interventions: BIOLOGICAL: HER-2/neu peptide vaccine|DRUG: cyclophosphamide|BIOLOGICAL: ex vivo-expanded HER2-specific T cells|OTHER: laboratory biomarker analysis|OTHER: flow cytometry|OTHER: immunoenzyme technique
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)